Biotech Press Releases

$NRXP Closing $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute Treatment Model and Leading Investigative Site

$NRXP NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP): Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) $NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

Cadrenal Therapeutics, Inc. (Stock Symbol: CVKD) $CVKD Tecarfarin Anticoagulant Reduces Drug on Drug Interactions Which Pose a Major Issue with Warfarin. Successful Phase III Could Enhance Liquidity and Quickly Attract Large Institutional Investors.

$NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties. NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)

$300 Million Set up in Milestones for $NRXP on Tiered Double-Digit Royalties

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) $NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP): License and Distribution Terms Set for Lucrative Suicide Depression Treatment; $31 Price Target from Respected Investment Analyst D. Boral Capital

$NRXP is Poised to Address the $3 Billion + Suicidal Depression Market in the US

$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAI

$NRXP Closing $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute Treatment Model and Leading Investigative Site

$NRXP NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP): Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) $NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

Cadrenal Therapeutics, Inc. (Stock Symbol: CVKD) $CVKD Tecarfarin Anticoagulant Reduces Drug on Drug Interactions Which Pose a Major Issue with Warfarin. Successful Phase III Could Enhance Liquidity and Quickly Attract Large Institutional Investors.

$NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties. NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)

$300 Million Set up in Milestones for $NRXP on Tiered Double-Digit Royalties

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) $NRXP Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties

NEXS BIOMEDICA CORPORATION, a leading innovator in biotechnology and pharmaceutical development, today announced a groundbreaking strategic partnership with Microsoft.

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP): License and Distribution Terms Set for Lucrative Suicide Depression Treatment; $31 Price Target from Respected Investment Analyst D. Boral Capital

$NRXP is Poised to Address the $3 Billion + Suicidal Depression Market in the US

$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAI

$RENB Collaboration with $NVDA to Employ NVIDIA AI Tech with Established GEDi CUBE as a Paradigm Shift for Early Disease Detection

Arsenale Bioyards a neo-industrial company fundamentally redefining scalable biomanufacturing, has announced the successful closure of its first $10 million seed financing round.

$NRXP given a $31 Price Target from Respected Investment Analyst D. Boral Capital

$NRXP $31 Price Target from Respected Investment Analyst D. Boral Capital

$NRXP New Drug Application for Treatment of Suicidal Depression. Completion of NDA Filing Expected in First Quarter of 2025

NRx Pharmaceuticals, Inc.: Stock Symbol: NRXP IS Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

$NRXP: Completion of NDA Filing Expected in First Quarter of 2025

$RENB is working with large $NVDA partner Nebul developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery

Ayurveda, Ayurvedic medicine, Ayurvedic Therapies, Ayurvedic supplements and yoga ( part of Ayurveda)  are growing rapidly in USA and Europe aside from India, according to Dr.Abhay Kumar Pati.

Marabou and Perlara Partner to Fund Research for Curing Rare Genetic Diseases, Aiming to Save Lives and Pave the Way for Longevity Studies

Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval

Genprex Stock Symbol: GNPX is Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes

NRXP: Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics.

Working With World-Class Institutions/Collaborators to Provide Novel Treatment Approaches. Stock Symbol: GNPX

Phronetik Joins a Nationwide Network Working to Accelerate Transformative Health Solutions

Creative Biolabs introduces innovative solutions for live biotherapeutics to empower scientists and pharmaceutical companies in their quest for groundbreaking therapies against gut diseases.

OLAB Bioscience, a global leader in industrial biotechnology specializing in algorithmic and AI-based solutions for synthetic biology, and CJ BIO, a prominent name in the bioproducts industry and business unit of South Korea-based CJ CheilJedang, are...

IVIEW Therapeutics Inc., a clinical stage biotechnology company advancing innovative treatments for ocular diseases, proudly announces the dosing of the first patient in the Phase 1/2 clinical trial of IVW-1001 Ophthalmic Eyelid Wipe.

Biorex Food Diagnostics announced today, the launch of its cutting-edge FlowSense product line, with the first phase designed specifically for the honey industry.

Quantoom Biosciences and Tiamat Sciences Announce Strategic Partnership to Revolutionize mRNA Production Quantoom Biosciences S.A.